Management of indolent mastocytosis and mast cell activation syndrome: A clinical yardstick.

Abstract

Knowledge and understanding of mast cell biology and mast cell disorders has increased in the past several years, with new classifications of diseases for both clonal and non-clonal forms. Along with these classifications has come differing treatment paradigms, including novel therapies now approved for various forms of clonal mast cell disorders. Unfortunately, there is some lack of guidance on how best to utilize these therapies. This yardstick aims to provide the clinician with a review of available therapies to treat mast cell activation syndrome and indolent systemic mastocytosis and an evidence-based expert opinion approach regarding how best to utilize these therapies.